期刊
JOURNAL OF CLINICAL GASTROENTEROLOGY
卷 47, 期 3, 页码 222-227出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCG.0b013e3182680221
关键词
hepatitis C; interleukins; protease inhibitors
资金
- Abbott
- Achillion
- BMS
- Gilead
- GSK
- Medtronic
- Merck
- Pfizer
- Roche
- Scynexis
- Vertex
The IL28B genotype is the strongest baseline predictor of hepatitis C treatment response with peginterferon-alpha and ribavirin. In 2011, 2 protease inhibitors were approved for genotype 1 infection in combination with peginterferon-alpha and ribavirin, and boceprevir and telaprevir attenuate the association between the IL28B genotype and treatment response. Although sustained virologic response rates are improved for all IL28B genotypes with the addition of the protease inhibitors, the unfavorable IL28B genotypes have substantial benefit. IL28B also predicts the likelihood of shortened duration of treatment with the protease inhibitor combination. As hepatitis C treatment moves towards interferon-free regimens, the role of IL28B in these regimens is under investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据